Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions of all types.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Progression free survival after pituitary surgery according to the clinicopathological classification (HYPOPRONOS) | Clinical, biochemical et imaging evaluation of a cohort of patient operated in the referral center for pituitary tumor. Identification of recurrence or progression an analysis of the clinicopathological classification. Evaluation of the different therapeutic strategies (med, surgery, chemotherapies, radiation therapy) to prevent recurrence or tumor progression. | up to 10 years (postoperatively) |
| Measure | Description | Time Frame |
|---|---|---|
| Correlation between percentage of SSTR expression of the pituitary tumor and somatostatine analogs efficacy. | Analysis of the expression of SST receptors in GH, PRL and ACTH secreting pituitary tumors: SSTR expression accessed by immunohistochemistry of the pituitary tumor. Evaluation of the response to somatostatine analogs: somatostatine analogs efficacy evaluated by normalization of hormone hypersecretion in ACTH, GH and PRL secreting pituitary tumor. |
Not provided
Inclusion Criteria:
• patients with confirmed pituitary disease
Exclusion Criteria:
• patients who do not have confirmed pituitary disease
Not provided
Not provided
Not provided
Not provided
tertiary referral center
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Gerald Raverot, MD PhD | Contact | (0)472119325 | +33 | gerald.raverot@chu-lyon.fr |
| Emmanuel Jouanneau, MD PhD | Contact | (0)472357411 | +33 | emmanuel.jouanneau@chu-lyon.fr |
| Name | Affiliation | Role |
|---|---|---|
| Gerald Raverot, MD PhD | Hospices Civils de Lyon | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Groupement Hospitalier Est, Lyon, France | Recruiting | Bron | 69500 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28651368 | Derived | Raverot G, Dantony E, Beauvy J, Vasiljevic A, Mikolasek S, Borson-Chazot F, Jouanneau E, Roy P, Trouillas J. Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3368-3374. doi: 10.1210/jc.2017-00773. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010911 | Pituitary Neoplasms |
| D000172 | Acromegaly |
| D015175 | Prolactinoma |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D007029 | Hypothalamic Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
DNA and pituitary tumor frozen sample (Neurobiotec Biological Resource Centre (BRC) of Hospices Civils de Lyon (HCL))
| 2007-2020 |
| Correlation between percentage of MGMT expression of the pituitary tumor and tumor response to temozolomide. | Evaluation of MGMT expression (accessed by immunohistochemistry of the pituitary tumor) and response to temozolomide treatment (evaluated according to RECIST criteria) for patient presenting multirecurrent tumors resistant to conventional treatment. | 2007-2020 |
| D015173 |
| Supratentorial Neoplasms |
| D001932 | Brain Neoplasms |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D007027 | Hypothalamic Diseases |
| D010900 | Pituitary Diseases |
| D004700 | Endocrine System Diseases |
| D001849 | Bone Diseases, Endocrine |
| D001847 | Bone Diseases |
| D009140 | Musculoskeletal Diseases |
| D006964 | Hyperpituitarism |
| D000236 | Adenoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |